Brokers Set Expectations for Fractyl Health FY2025 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Fractyl Health in a report issued on Thursday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($1.15) per share for the year, up from their previous forecast of ($1.72). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2025 earnings at ($0.14) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.31 EPS.

Several other equities analysts have also weighed in on the company. Canaccord Genuity Group cut their target price on Fractyl Health from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Wednesday, October 8th. Finally, LADENBURG THALM/SH SH began coverage on Fractyl Health in a research note on Thursday, August 28th. They issued a “buy” rating and a $3.60 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.90.

Fractyl Health Price Performance

GUTS opened at $1.26 on Monday. The company has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.46. The company has a debt-to-equity ratio of 4.61, a quick ratio of 4.27 and a current ratio of 4.27. The firm has a market capitalization of $63.37 million, a PE ratio of -0.55 and a beta of 2.21. Fractyl Health has a 52 week low of $0.83 and a 52 week high of $3.03.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GUTS. Burkehill Global Management LP bought a new stake in shares of Fractyl Health during the third quarter worth approximately $795,000. Shay Capital LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $453,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Fractyl Health in the 3rd quarter valued at $56,000. Rosalind Advisors Inc. bought a new stake in Fractyl Health in the 3rd quarter valued at $7,950,000. Finally, UBS Group AG grew its holdings in Fractyl Health by 3,194.8% in the 3rd quarter. UBS Group AG now owns 752,596 shares of the company’s stock valued at $1,197,000 after buying an additional 729,754 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.